{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:31:13Z","timestamp":1794267073543,"version":"4.9.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.tube.2022.102288","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T03:05:08Z","timestamp":1669691108000},"page":"102288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Microbiological profile, preclinical pharmacokinetics and efficacy of CRS0393, a novel antimycobacterial agent targeting MmpL3"],"prefix":"10.1016","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0959-0265","authenticated-orcid":false,"given":"Urs A.","family":"Ochsner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"De Groote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thale C.","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Youmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Ribble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camron","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra M.","family":"Panthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binayak","family":"Rimal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey M.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen I.","family":"Zgurskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Ordway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Gonzalez-Juarrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xicheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyanu","family":"Lamichhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2022.102288_bib1","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1513\/AnnalsATS.201503-173OC","article-title":"The burden of pulmonary nontuberculous mycobacterial disease in the United States","volume":"12","author":"Strollo","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.tube.2022.102288_bib2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1513\/AnnalsATS.201804-236OC","article-title":"Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. Managed Care health plan, 2008-2015","volume":"17","author":"Winthrop","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.tube.2022.102288_bib3","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3390\/jcm9082541","article-title":"General overview of nontuberculous mycobacteria opportunistic pathogens: Mycobacterium avium and Mycobacterium abscessus","volume":"9","author":"To","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.tube.2022.102288_bib4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1164\/rccm.201807-1273PP","article-title":"Advancing translational science for pulmonary nontuberculous mycobacterial infections. A road map for research","volume":"199","author":"Daniel-Wayman","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2022.102288_bib5","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1164\/rccm.201111-2016OC","article-title":"Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries","volume":"185","author":"Adjemian","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2022.102288_bib6","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jcf.2017.01.017","article-title":"High incidence of non-tuberculous mycobacteria-positive cultures among adolescent with cystic fibrosis","volume":"16","author":"Cavalli","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.tube.2022.102288_bib7","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1086\/504381","article-title":"Infections due to rapidly growing mycobacteria","volume":"42","author":"De Groote","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2022.102288_bib8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0272-5231(02)00019-9","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria","volume":"23","author":"Marras","year":"2002","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.tube.2022.102288_bib9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40506-016-0092-6","article-title":"Nontuberculous mycobacteria in cystic fibrosis","volume":"8","author":"Skolnik","year":"2016","journal-title":"Curr Treat Options Infect Dis"},{"key":"10.1016\/j.tube.2022.102288_bib10","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1513\/AnnalsATS.201709-727OC","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010-2014","volume":"15","author":"Adjemian","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.tube.2022.102288_bib11","author":"Hasan"},{"key":"10.1016\/j.tube.2022.102288_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijid.2015.01.014","article-title":"The complex evolution of antibiotic resistance in Mycobacterium tuberculosis","volume":"32","author":"Fonseca","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.tube.2022.102288_bib13","doi-asserted-by":"crossref","DOI":"10.1080\/17476348.2019.1638765","article-title":"Managing antibiotic resistance in nontuberculous mycobacterial pulmonary disease: challenges and new approaches","author":"Kwon","year":"2019","journal-title":"Expet Rev Respir Med"},{"key":"10.1016\/j.tube.2022.102288_bib14","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccm.2014.10.004","article-title":"The treatment of rapidly growing mycobacterial infections","volume":"36","author":"Kasperbauer","year":"2015","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.tube.2022.102288_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.drup.2012.04.001","article-title":"Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria","volume":"15","author":"van Ingen","year":"2012","journal-title":"Drug Resist Updates"},{"key":"10.1016\/j.tube.2022.102288_bib16","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12916-016-0606-6","article-title":"'\"Why me, why now?\" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection","volume":"14","author":"Lake","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.tube.2022.102288_bib17","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.rmed.2009.04.026","article-title":"Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs","volume":"103","author":"Ballarino","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.tube.2022.102288_bib18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/QCO.0b013e328055d9a2","article-title":"Therapy of nontuberculous mycobacterial disease","volume":"20","author":"Griffith","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.tube.2022.102288_bib19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QCO.0b013e328336ead6","article-title":"Nontuberculous mycobacterial lung disease","volume":"23","author":"Griffith","year":"2010","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.tube.2022.102288_bib20","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1183\/09031936.00055010","article-title":"The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada","volume":"37","author":"Leber","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2022.102288_bib21","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/microorganisms7030090","article-title":"Mycobacterium abscessus: environmental bacterium turned clinical nightmare","volume":"7","author":"Lopeman","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.tube.2022.102288_bib22","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jac\/dkr578","article-title":"Mycobacterium abscessus: a new antibiotic nightmare","volume":"67","author":"Nessar","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib41","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.2174\/1389557516666160118105319","article-title":"MmpL3 inhibitors: diverse chemical scaffolds inhibit the same target","volume":"16","author":"Poce","year":"2016","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.tube.2022.102288_bib23","article-title":"Clinical characteristics and treatment outcomes of patients with acquired macrolide-resistant Mycobacterium abscessus lung disease","volume":"61","author":"Choi","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib24","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.chest.2017.04.166","article-title":"Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis","volume":"152","author":"Diel","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.tube.2022.102288_bib26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ijantimicag.2016.10.024","article-title":"Antimicrobial susceptibility and MIC distribution of 41 drugs against clinical isolates from China and reference strains of nontuberculous mycobacteria","volume":"49","author":"Li","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2022.102288_bib27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMp1314385","article-title":"FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis","volume":"371","author":"Cox","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tube.2022.102288_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01919-18","article-title":"In vitro susceptibility testing of bedaquiline against Mycobacterium abscessus complex","volume":"63","author":"Brown-Elliott","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/infdis\/jit614","article-title":"In vivo evaluation of antibiotic activity against Mycobacterium abscessus","volume":"209","author":"Lerat","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2022.102288_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1378\/chest.14-2764","article-title":"Preliminary results of bedaquiline as salvage therapy for patients with nontuberculous mycobacterial lung disease","volume":"148","author":"Philley","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.tube.2022.102288_bib31","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2022.102288_bib32","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jac\/dky526","article-title":"A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria","volume":"74","author":"Ruth","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib33","first-page":"CD010004","article-title":"Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis","volume":"12","author":"Waters","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tube.2022.102288_bib34","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.bbrc.2006.09.132","article-title":"Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells","volume":"350","author":"Cigana","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.tube.2022.102288_bib35","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.3389\/fmicb.2018.02231","article-title":"Optimization and lead selection of benzothiazole amide analogs toward a novel antimycobacterial agent","volume":"9","author":"De Groote","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.tube.2022.102288_bib36","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1016\/j.bmcl.2018.08.026","article-title":"Discovery of benzothiazole amides as potent antimycobacterial agents","volume":"28","author":"Graham","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.tube.2022.102288_bib37","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1128\/AAC.00826-16","article-title":"Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3","volume":"60","author":"Li","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib38","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1128\/AAC.03229-14","article-title":"Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib39","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3389\/fmicb.2018.01547","article-title":"MmpL3 as a target for the treatment of drug-resistant nontuberculous mycobacterial infections","volume":"9","author":"Li","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.tube.2022.102288_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056980","article-title":"Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection","volume":"8","author":"Poce","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tube.2022.102288_bib42","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1517\/14728222.2014.859677","article-title":"MmpL3 a potential new target for development of novel anti-tuberculosis drugs","volume":"18","author":"Rayasam","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.tube.2022.102288_bib43","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1021\/acs.jmedchem.6b00415","article-title":"Indole-2-carboxamide-based MmpL3 inhibitors show exceptional antitubercular activity in an animal model of tuberculosis infection","volume":"59","author":"Stec","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2022.102288_bib44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21292\/2075-1230-2018-96-3-6-18","article-title":"Efficiency and safety of chemotherapy regimen with SQ109 in those suffering from multiple drug resistant tuberculosis","volume":"96","author":"Borisov","year":"2018","journal-title":"Tuberculosis and Lung Diseases"},{"key":"10.1016\/j.tube.2022.102288_bib45","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2217\/fmb.12.56","article-title":"Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action","volume":"7","author":"Sacksteder","year":"2012","journal-title":"Future Microbiol"},{"key":"10.1016\/j.tube.2022.102288_bib46","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1128\/AAC.05708-11","article-title":"SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis","volume":"56","author":"Tahlan","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib47","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ajic.2014.05.014","article-title":"Analysis of a panel of rapidly growing mycobacteria for resistance to aldehyde-based disinfectants","volume":"42","author":"De Groote","year":"2014","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.tube.2022.102288_bib48","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S1473-3099(17)30324-9","article-title":"Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study","volume":"17","author":"van Ingen","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tube.2022.102288_bib49","series-title":"M24 supplement (M62","article-title":"Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes","year":"2018"},{"key":"10.1016\/j.tube.2022.102288_bib50","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejcdt.2013.05.008","article-title":"Resazurin Microtiter Assay Plate method for detection of susceptibility of multidrug resistant Mycobacterium tuberculosis to second-line anti-tuberculous drugs","volume":"62","author":"Khalifa","year":"2013","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"10.1016\/j.tube.2022.102288_bib51","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1021\/acsinfecdis.9b00048","article-title":"Direct inhibition of MmpL3 by novel antitubercular compounds","volume":"5","author":"Li","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.tube.2022.102288_bib52","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput Methods Progr Biomed"},{"key":"10.1016\/j.tube.2022.102288_bib53","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF01062139","article-title":"Testing for the equality of area under the curves when using destructive measurement techniques","volume":"16","author":"Bailer","year":"1988","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.tube.2022.102288_bib54","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1038\/s41598-020-60452-1","article-title":"A mouse model of pulmonary Mycobacteroides abscessus infection","volume":"10","author":"Maggioncalda","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.tube.2022.102288_bib55","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1128\/AAC.00459-15","article-title":"Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models","volume":"59","author":"Obregon-Henao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib56","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jac\/dkw417","article-title":"Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo","volume":"72","author":"Ammerman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47159-8","article-title":"The MmpL3 interactome reveals a complex crosstalk between cell envelope biosynthesis and cell elongation and division in mycobacteria","volume":"9","author":"Belardinelli","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.tube.2022.102288_bib58","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/mmi.13283","article-title":"Insights into the smooth-to-rough transitioning in Mycobacterium bolletii unravels a functional Tyr residue conserved in all mycobacterial MmpL family members","volume":"99","author":"Bernut","year":"2016","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.tube.2022.102288_bib59","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.cell.2019.01.003","article-title":"Crystal structures of membrane transporter MmpL3, an anti-TB drug target","volume":"176","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.tube.2022.102288_bib60","author":"Maggioncalda"},{"key":"10.1016\/j.tube.2022.102288_bib61","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1016\/j.bmc.2017.05.015","article-title":"Design, synthesis and evaluation of indole-2-carboxamides with pan anti-mycobacterial activity","volume":"25","author":"Franz","year":"2017","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.tube.2022.102288_bib62","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/mmi.13406","article-title":"A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus","volume":"101","author":"Dupont","year":"2016","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.tube.2022.102288_bib63","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1021\/acsinfecdis.6b00095","article-title":"Structure-function profile of MmpL3, the essential mycolic acid transporter from Mycobacterium tuberculosis","volume":"2","author":"Belardinelli","year":"2016","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.tube.2022.102288_bib64","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1186\/1756-0500-4-466","article-title":"Acidochromogenicity is a common characteristic in nontuberculous mycobacteria","volume":"4","author":"Saviola","year":"2011","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.tube.2022.102288_bib65","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1046\/j.1432-1327.2001.02275.x","article-title":"Expression and functional analysis of a gene cluster involved in the synthesis of decaprenoxanthin reveals the mechanisms for C50 carotenoid formation","volume":"268","author":"Krubasik","year":"2001","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.tube.2022.102288_bib66","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01704-21","article-title":"Potency of omadacycline against mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection","volume":"66","author":"Nicklas","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib67","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/jac\/dkt451","article-title":"GM-CSF knockout mice for preclinical testing of agents with antimicrobial activity against Mycobacterium abscessus","volume":"69","author":"De Groote","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib68","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1128\/AAC.00464-12","article-title":"Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery","volume":"56","author":"Gonzalez-Juarrero","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.tube.2022.102288_bib69","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/S1569-1993(11)60021-0","article-title":"The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease","volume":"10","author":"Zhou","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.tube.2022.102288_bib70","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1128\/AAC.02346-12","article-title":"Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis","volume":"57","author":"Dharmadhikari","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102288_bib71","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.tube.2022.102288_bib72","doi-asserted-by":"crossref","first-page":"ofy034","DOI":"10.1093\/ofid\/ofy034","article-title":"Positive effect of liposomal amikacin for inhalation on Mycobacterium abcessus in cystic fibrosis patients","volume":"5","author":"Caimmi","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.tube.2022.102288_bib73","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.2147\/DDDT.S146111","article-title":"The use of amikacin liposome inhalation suspension (Arikayce) in the treatment of refractory nontuberculous mycobacterial lung disease in adults","volume":"14","author":"Khan","year":"2020","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.tube.2022.102288_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108703","article-title":"Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection","volume":"9","author":"Rose","year":"2014","journal-title":"PLoS One"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979222001251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979222001251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:49:11Z","timestamp":1761468551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979222001251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":74,"alternative-id":["S1472979222001251"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2022.102288","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microbiological profile, preclinical pharmacokinetics and efficacy of CRS0393, a novel antimycobacterial agent targeting MmpL3","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2022.102288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102288"}}